Poster presentations related to multiple myeloma will take place primarily the morning of Monday, June 6, at the 2016 American Society of Clinical Oncology (ASCO) annual meeting.

The list below contains the titles and authors of all multiple myeloma poster presentations at ASCO 2016. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.

Links to PDF files containing posters will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.

This edition of Myeloma Morning gives a quick overview of the myeloma-related poster presentations at the ASCO 2016 meeting.

The Beacon also has complete lists of all ASCO 2016 multiple myeloma-related oral presentations, education session presentations, and e-abstracts, as well as news articles about multiple myeloma at the ASCO 2016 meeting.

We want to thank the Beacon's sponsors for making it possible for The Beacon to provide this and other important news, information, and support to the multiple myeloma community worldwide.

---

Session	Health Services Research and Quality of Care
Type	Poster Session
Time	Saturday June 4, 1:00 PM - 4:30 PM
Location	Hall A

---

6621 - Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE

Hartmut Goldschmidt, Ravi Vij, David Kuter, David Cella, Teresa Maria Zyczynski, Catherine C. Davis, Sergey Popov, Gordon Cook (abstract)

---

Session	Hematologic Malignancies - Plasma Cell Dyscrasia
Type	Poster Session
Time	Monday June 6, 8:00 AM to 11:30 AM
Location	Hall A

---

8012 - MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study

Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor W Blau, Hermann Einsele, Monika Martha Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja Weisel, Pia Kloepfer, Dominika Weinelt, Jan Endell, Rainer Boxhammer, Christian Peschel (abstract, poster [PDF])

8013 - Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM)

Rachid C. Baz, Kenneth H. Shain, Melissa Alsina, Jason Brayer, Tami Rashal, Jennifer L Cooksey, Joel G Turner, Jana Dawson, Daniel Sullivan (abstract, poster [PDF] courtesy of Rachid C. Baz)

8014 - Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma

Jacob Laubach, Sascha Alexander Tuchman, Jacalyn Rosenblatt, Robert Redd, Kathleen Colson, Ashley Motta, Kathleen Fitzpatrick, Edie Weller, Paul G. Richardson (abstract)

8015 - Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression

Wilson I. Gonsalves, S. Vincent Rajkumar, Michael Timm, William Morice, Angela Dispenzieri, Martha Lacy, Francis Buadi, David Dingli, Ronald S. Go, Nelson Leung, Prashant Kapoor, Suzanne R. Hayman, John Anthony Lust, Stephen Russell, Steven R. Zeldenrust, Taxiarchis Kourelis, Yi Lisa Hwa, Robert A. Kyle, Morie A. Gertz, Shaji Kumar (abstract)

8017 - Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma

Nidhi Tandon, S.Vincent Rajkumar, Martha Lacy, Angela Dispenzieri, Francis Buadi, Morie A. Gertz, Suzanne R. Hayman, Nelson Leung, Ronald S. Go, David Dingli, Prashant Kapoor, Yi Lin, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Steven R. Zeldenrust, John Anthony Lust, Wilson I. Gonsalves, Stephen Russell, Shaji Kumar (abstract)

8018 - Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III TOURMALINE-MM1 study

Paul G. Richardson, Hervé Avet-Loiseau, Antonio Palumbo, Luisa Viterbo, Arnon Nagler, Peter Ganly, Dina Ben Yehuda, Jesus San Miguel, S.Vincent Rajkumar, Ludek Pour, Christian Langer, Nizar J. Bahlis, Andrzej Pluta, Tamas Masszi, Deborah Berg, Jianchang Lin, Helgi Van De Velde, Dixie-Lee Esseltine, Alessandra di Bacco, Philippe Moreau (abstract, poster [PDF])

8019 - Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM)

Bei Hu, Koji Sasaki, Qaiser Bashir, Nina Shah, Krina K. Patel, Uday R. Popat, Chitra Hosing, Yago Nieto, Pei Lin, Ruby Delgado, Jeffrey L. Jorgensen, Jatin J. Shah, Elisabet Esteve Manasanch, Donna M. Weber, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash (abstract)

8020 - Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials

Ajay K. Nooka, Jonathan L. Kaufman, Sagar Lonial (abstract)

8021 - Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM)

Andrzej J. Jakubowiak, Agnes Benedict, Sumeet Panjabi, Ivan Houisse, Marco Campioni, Andromachi Giannopoulou, Sanjay Aggarwal, Rafael Fonseca (abstract)

8022 - Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM)

Safiya Abouzaid, Kejal Parikh, Zheng-Yi Zhou, Zhou Zhou, Wenxi Tang, Jipan Xie, Manali I. Patel (abstract)

8023 - Can comorbidities predict survival of patients with multiple myeloma treated with autologous stem cell transplantation?

Aleksandra Pivkova Veljanovska, Zlate Stojanoski, Lazar Chadievski, Lidija Cevreska, Borce Georgievski, Sonja Genco Genadieva-Stavrik (abstract)

8024 - Comparison of three leukapharesis machines for harvest of stem cells for autologous transplantation: A prospective study

Rakesh Reddy, Atul Sharma, Sameer Bakhshi, Ajay Gogia, Ranjit Sahoo, Chander Prakash Yadav, Lalit Kumar (abstract)

8026 - Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma

Amarendra Kumar Neppalli, Judith Shizuru, Laura J. Johnston, Lori S. Muffly, Wen-Kai Weng, Robert Negrin, Everett Meyer, Ginna Laport, Robert Lowsky, Sally Arai, David Bernard Miklos, Andrew R. Rezvani (abstract)

8027 - Melphalan + Bortezomib (MelVel) and Mel + Vel + Thalidomide (MelVelThal) as a conditioning regimen for autologous peripheral blood stem cell transplantation (ASCT) in patients (pts) with advanced multiple myeloma (MM): An updated analysis of 2 phase I/II studies

Shijia Zhang, Noa Biran, David Samuel DiCapua Siegel, Michele Donato, David H. Vesole, Andrew Pecora, Joshua Ryan Richter, Alan P. Skarbnik, Andre Goy, Stuart L. Goldberg, Tatyana A. Feldman, Emily Brown, Kathryn Buttner, Marie DelFavero, Sung H. Hong, Daniel Kim, Scott D. Rowley (abstract)

8028 - Role of PET/CT in prognosticating post-transplant outcomes based on a new scoring system: Results of PIPET-M TRIAL

Uday Yanamandra, B.R. Mittal, Arun Reddy, Kanhaiya Agarwal, Alka Khadwal, Gaurav Prakash, Neelam Varma, Subhash Varma, Pankaj Malhotra (abstract)

8029 - Is 18F-FDG-PET/CT a good MRD marker in patients with multiple myeloma? Comparison and correlation with biochemical markers/flowcytometry

Uday Yanamandra, B.R. Mittal, Arun Reddy, Kanhaiya Agarwal, Alka Khadwal, Gaurav Prakash, Neelam Varma, Subhash Varma, Pankaj Malhotra (abstract)

8030 - Role of inflammation gene polymorphisms on pain and response to radiotherapy in multiple myeloma patients with painful bone destructions

Milda Rudzianskiene, Arturas Inciura, Rolandas Gerbutavicius, Ruta Dambrauskiene, Viktoras Rudzianskas, Elona Juozaityte (abstract)

8031 - Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials

Philippe Moreau, Meletios A. Dimopoulos, Paul G. Richardson, David Samuel DiCapua Siegel, Antonio Palumbo, Michele Cavo, Paolo Corradini, Katja Weisel, Michel Delforge, Peter O'Gorman, Kevin W. Song, Lars Axel Sternas, Teresa Peluso, Kevin Hong, Jennifer Herring, Xin Yu, Mohamed H. Zaki, Jesus San Miguel (abstract)

8032 - Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma

Shaji Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Brigitte Pegourie, Lotfi Benboubker, Cristina Gasparetto, Martine Amiot, Philippe Moreau, Susan Diehl, Stefanie Alzate, Jeremy A Ross, Martin Dunbar, Ming Zhu, Suresh K Agarwal, Joel Leverson, Paulo Cesar Maciag, Maria E. Verdugo, Cyrille Touzeau (abstract, poster [PDF] courtesy of Shaji Kumar)

8033 - The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics

Rajshekhar Chakraborty, Eli Muchtar, Shaji Kumar, Francis Buadi, David Dingli, Angela Dispenzieri, Suzanne R. Hayman, William J. Hogan, Prashant Kapoor, Martha Lacy, Nelson Leung, Morie A. Gertz (abstract)

8034 - Clinical utility of comprehensive approach to detect genetic abnormalities in multiple myeloma

Hyun Ae Jung, Mi-Ae Jang, Seok Jin Kim, Kihyun Kim (abstract)

8035 - Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset

Aishwarya Ravindran, Adam C. Bartley, Aneel A. Ashrani, Wilson I. Gonsalves, Shahrukh K. Hashmi, Prashant Kapoor, Ariela L. Marshall, Mustaqeem Ahmad Siddiqui, Angela Dispenzieri, Robert A. Kyle, S.Vincent Rajkumar, Ronald S. Go (abstract)

8036 - Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1

Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Zhou Daobin, Jin Lou, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Bingxia Wang, Xiaoquan Zhang, Hui Wang, Helgi Van De Velde, Paul G. Richardson, Philippe Moreau (abstract, poster [PDF])

8037 - ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) – Identifying responders by subset analysis

Sagar Lonial, Paul G. Richardson, María-Victoria Mateos, Katja Weisel, Meletios A. Dimopoulos, Philippe Moreau, Oumar Sy, Jessica Katz, Manish Gupta, Antonio Palumbo (abstract)

8038 - Real world health and economic outcomes in patients with non-stem cell transplant (NSCT) multiple myeloma initially treated with lenalidomide and/or bortezomib-based regimens

Kejal Parikh, Safiya Abouzaid, Chi-Chang Chen, Catherine Balderston McGuiness, Rolin L. Wade (abstract)

8039 - Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM

María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Ludek Pour, Luisa Viterbo, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Helgi Van De Velde, Paul G. Richardson, Philippe Moreau (abstract, poster [PDF])

8040 - Comparison of plasma cell infiltration in random samples of the bone marrow and osteolyses acquired by CT-guided biopsy in patients with symptomatic multiple myeloma

Jens Hillengass, Elena Ellert, Daniel Spira, Stefan Hemmer, Berbara Wagner, Mindaugas Andrulis, Sandra Sauer (abstract)

8041 - Retrospective claims analysis of patient factors affecting multi-line treatment patterns in multiple myeloma (MM)

Safiya Abouzaid, Kejal Parikh, Chi-Chang Chen, Catherine Balderston McGuiness, Rolin L. Wade, Ajai Chari (abstract)

8042 - Real world treatment patterns, time to next treatment and economic outcomes in relapsed multiple myeloma patients treated with pomalidomide or carfilzomib

Kejal Parikh, Lea Purnomo, Safiya Abouzaid, Chi-Chang Chen, Catherine Balderston McGuiness, Mohamad A. Hussein, Rolin L. Wade (abstract)

8043 - Transitions across different lines of therapy in Medicare-enrolled patient populations with multiple myeloma

Akeem Yusuf, Tanya Natwick, Diana Felici, Winifred Werther (abstract)

8044 - Evaluation of serum Cystatin-C as a prognostic and predictive factor in patients with newly diagnosed multiple myeloma

Rakesh Reddy, Ritu Gupta, Nitin Mathur, Lata Rani, Atul Sharma, Lalit Kumar (abstract)

8045 - Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391)

Heinz Ludwig, Meletios A. Dimopoulos, Tamas Masszi, Ivan Spicka, Albert Oriol Rocafiguera, Roman Hajek, Laura Rosinol, David Samuel DiCapua Siegel, Georgi Mihaylov, Vesselina Goranova-Marinova, Peter Rajnics, Aleksandr Suvorov, Ruben Niesvizky, Andrzej J. Jakubowiak, Jesus San Miguel, Mihaela Obreja, Sanjay Aggarwal, Philippe Moreau, Antonio Palumbo (abstract)

8046 - Treatment regimens and duration of lines of therapy in Medicare-enrolled patients with multiple myeloma

Akeem Yusuf, Tanya Natwick, Diana Felici, Winifred Werther (abstract)

8047 - Health-related quality of life over time in transplant-ineligible patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone until progression

Dan T. Vogl, Michel Delforge, Kevin W. Song, Shien Guo, Craig J Gibson, Annette L. Ervin-Haynes, Thierry Facon (abstract)

8048 - Costs associated with treatment induced peripheral neuropathy in patients with multiple myeloma (MM)

Sumeet Panjabi, Xue Song, Kathleen Wilson, Jerry Kagan (abstract)

8049 - Risk of hypertension (HTN) and malignant hypertension (mHTN) in patients treated for multiple myeloma (MM)

Ajai Chari, Sanjay Aggarwal, Khalid Mezzi, Shao Zhu, Winifred Werther, Diana Felici, Alexander R. Lyon (abstract)

8050 - Dysregulation of nuclear factor-kappaB pathway in multiple myeloma patients at diagnosis and relapse

Shivali Jasrotia, Ritu Gupta, Sobuhi Iqbal, Atul Sharma, Ashutosh Halder, Lalit Kumar (abstract)

8051 - Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients

Jule Franve Vasquez Chavez, Rossana Esther Ruiz Mendoza, Karina Mayra Aliaga Llerena, Fernando Valencia, Daniel Enriquez, Victor Palacios, Luis Casanova (abstract)

8052 - Real-world utilization patterns of PI and IMiD combination therapy as treatment for relapse multiple myeloma

Eric M. Maiese, Terra Slaton, Brian Macomson, Chris M. Kozma (abstract)

8053 - Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma

Nidhi Tandon, Martha Lacy, Francis Buadi, Nelson Leung, Ronald S. Go, David Dingli, Prashant Kapoor, Morie A. Gertz, Yi Lin, Angela Dispenzieri, Matthew Drake, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Suzanne R. Hayman, Steven R. Zeldenrust, John Anthony Lust, Wilson I. Gonsalves, S.Vincent Rajkumar, Shaji Kumar (abstract)

8054 - Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial

Paul G. Richardson, Sagar Lonial, Robert L. Schlossman, Anuja Nidumolu Roy, Istvan Majer, Ashok Panneerselvam, Monika Sopala, Jesus San Miguel (abstract)

8055 - Validation of a thrombosis risk assessment model in patients with newly diagnosed multiple myeloma

Brea Lipe, Hailey Baker, Brandon Weckbaugh, Carol Webb, Alexandra Brown, Jonathan Mahnken, Theresa Shireman (abstract)

8056 - Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM)

Scott Ely, Peter Forsberg, Ruben Niesvizky, Tomer Martin Mark (abstract)

8057 - Cost per median overall month of survival in multiple myeloma patients with ≥3 lines of therapy or were double refractory

Eric M. Maiese, Maria Dimova, Gianluca Baio, Charles Makin (abstract)

8058 - Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM)

Heidi Diann Finnes, Shaji Kumar, Betsy LaPlant, Morie A. Gertz, Francis Buadi, Martha Lacy, Angela Dispenzieri, Kristen Beth McCullough, Julianna A. Merten, Gabriel T. Bartoo, S. Vincent Rajkumar, Prashant Kapoor (abstract)

8059 - Healthcare costs among multiple myeloma (MM) patients (Pts) without stem cell transplant (SCT)

Sumeet Panjabi, May Hagiwara, Arati Sharma, Yaozhu (Juliette) J. Chen, Thomas E. Delea (abstract)

8060 - Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs)

May Hagiwara, Sumeet Panjabi, Arati Sharma, Yaozhu (Juliette) J. Chen, Thomas E. Delea (abstract)

8061 - Second-line prescribing preferences of U.S. hematology-oncology physicians for patients (pts) with recurrent multiple myeloma (MM): Impact of novel agents

Robert Z. Orlowski, Joanne P. Willey, Maria L. Lankford, Arden Buettner, Stewart Kaufman, Susan Lynne Britton, Mitchell Scharf, Brynn Tiscione, Doug B. Neely, Joel H. Schwartz (abstract)

8062 - Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes

Surbhi Sidana, S. Vincent Rajkumar, Angela Dispenzieri, Martha Lacy, Morie A. Gertz, Francis Buadi, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Wilson I. Gonsalves, Yi Lisa Hwa, Nelson Leung, Amie Fonder, Miriam Hobbs, Steven R. Zeldenrust, Stephen J. Russell, John Anthony Lust, Robert A. Kyle, Shaji Kumar (abstract)

8064 - High serum free light chain concentration (>1000mg/dl) at the time of relapse to predict poor prognosis in multiple myeloma

Abhishek Chilkulwar, Anna Miller, Prerna Mewawalla, Gina Berteotti, Anna Kaminsky, Santhosh Sadhashiv, Entezam A. Sahovic, John Lister (abstract)